Hepatocellular Carcinoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Hepatocellular Carcinoma – Pipeline Review, H1 2017’, provides an overview of the Hepatocellular Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma

The report reviews pipeline therapeutics for Hepatocellular Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hepatocellular Carcinoma therapeutics and enlists all their major and minor projects

The report assesses Hepatocellular Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

AbbVie Inc

Abivax SA

Acceleron Pharma Inc

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

Alfact Innovation

Amgen Inc

AndroScience Corp

ArQule Inc

Array BioPharma Inc

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Bio-Cancer Treatment International Ltd

Biomics Biotechnologies Co Ltd

Bioneer Corp

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Can-Fite BioPharma Ltd

CASI Pharmaceuticals Inc

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Celsion Corp

China Medical System Holdings Ltd

Chugai Pharmaceutical Co Ltd

Conatus Pharmaceuticals Inc

Delcath Systems Inc

Dicerna Pharmaceuticals Inc

Double Bond Pharmaceutical International AB

eFFECTOR Therapeutics Inc

Eiger BioPharmaceuticals Inc

Eisai Co Ltd

Eli Lilly and Company

Endocyte Inc

Epeius Biotechnologies Corp

eTheRNA Immunotherapies NV

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Galaxy Biotech LLC

Genelux Corp

Genoscience Pharma

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Golden Biotechnology Corp

Green Cross Cell Corp

Green Cross Corp

H3 Biomedicine Inc

HanAll Biopharma Co Ltd

Horizon Pharma Plc

Humorigin Biotechnology Corp

Immatics Biotechnologies GmbH

Immune Therapeutics Inc

Immunicum AB

Immunitor Inc

Immunomedics Inc

Immunovative Therapies Ltd

In-Cell-Art SAS

Incyte Corp

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

InteRNA Technologies BV

Jenrin Discovery Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

KAHR medical Ltd

Karcinolys SAS

Kite Pharma Inc

Komipharm International Co Ltd

Kowa Company Ltd

Les Laboratoires Servier SAS

Ligand Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

MaxCyte Inc

MedImmune LLC

Medivir AB

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

Mina Therapeutics Ltd

MTG Biotherapeutics Inc

MultiCell Technologies Inc

NeuroVive Pharmaceutical AB

NormOxys Inc

Novartis AG

NovaTarg Therapeutics Inc

Nymox Pharmaceutical Corp

Omeros Corp

Oncolys BioPharma Inc

OncoMed Pharmaceuticals Inc

OncoTherapy Science Inc

Oneness Biotech Co Ltd

Ono Pharmaceutical Co Ltd

Onxeo SA

Otsuka Holdings Co Ltd

Panacea Pharmaceuticals Inc

PepVax Inc

Peregrine Pharmaceuticals Inc

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

PharmaEssentia Corp

Provecs Medical GmbH

Provectus Biopharmaceuticals Inc

Q BioMed Inc

RedHill Biopharma Ltd

Regulus Therapeutics Inc

Saronic Biotechnology Inc

Shenogen Pharma Group Ltd

Sillajen Biotherapeutics

Simcere Pharmaceutical Group

Sun Pharma Advanced Research Company Ltd

Taiwan Liposome Company Ltd

Takeda Pharmaceutical Company Ltd

TC BioPharm Ltd

tella Inc

Tessa Therapeutics Pte Ltd

Therapure Biopharma Inc

Theravectys SA

Threshold Pharmaceuticals Inc

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

Tumorend LLC

UbiVac LLC

VasGene Therapeutics Inc

Vaxon Biotech

Vect-Horus SAS

Verlyx Pharma Inc

VG Life Sciences Inc

Vicus Therapeutics LLC

Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Hepatocellular Carcinoma - Overview 9

Hepatocellular Carcinoma - Therapeutics Development 10

Hepatocellular Carcinoma - Therapeutics Assessment 41

Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 61

Hepatocellular Carcinoma - Drug Profiles 134

Hepatocellular Carcinoma - Dormant Projects 963

Hepatocellular Carcinoma - Discontinued Products 970

Hepatocellular Carcinoma - Product Development Milestones 973

Appendix 986

List of Tables

List of Tables

Number of Products under Development for Hepatocellular Carcinoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hepatocellular Carcinoma – Pipeline by AB Science SA, H1 2017

Hepatocellular Carcinoma – Pipeline by AbbVie Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Abivax SA, H1 2017

Hepatocellular Carcinoma – Pipeline by Acceleron Pharma Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Hepatocellular Carcinoma – Pipeline by Advenchen Laboratories LLC, H1 2017

Hepatocellular Carcinoma – Pipeline by Alfact Innovation, H1 2017

Hepatocellular Carcinoma – Pipeline by Amgen Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by AndroScience Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by ArQule Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Array BioPharma Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by AstraZeneca Plc, H1 2017

Hepatocellular Carcinoma – Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Bayer AG, H1 2017

Hepatocellular Carcinoma – Pipeline by BeiGene Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Bio-Cancer Treatment International Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Biomics Biotechnologies Co Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Bioneer Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Blueprint Medicines Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Hepatocellular Carcinoma – Pipeline by Boston Biomedical Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Bristol-Myers Squibb Company, H1 2017

Hepatocellular Carcinoma – Pipeline by Can-Fite BioPharma Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by CASI Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by CBT Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by CCRP Therapeutics GmbH, H1 2017

Hepatocellular Carcinoma – Pipeline by Celgene Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Celldex Therapeutics Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Celsion Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by China Medical System Holdings Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Delcath Systems Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Dicerna Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Double Bond Pharmaceutical International AB, H1 2017

Hepatocellular Carcinoma – Pipeline by eFFECTOR Therapeutics Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Eiger BioPharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Eisai Co Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Eli Lilly and Company, H1 2017

Hepatocellular Carcinoma – Pipeline by Endocyte Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Epeius Biotechnologies Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by eTheRNA Immunotherapies NV, H1 2017

Hepatocellular Carcinoma – Pipeline by Exelixis Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Faron Pharmaceuticals Oy, H1 2017

Hepatocellular Carcinoma – Pipeline by Galaxy Biotech LLC, H1 2017

Hepatocellular Carcinoma – Pipeline by Genelux Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Genoscience Pharma, H1 2017

Hepatocellular Carcinoma – Pipeline by Genosco Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Gilead Sciences Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by GlaxoSmithKline Plc, H1 2017

Hepatocellular Carcinoma – Pipeline by Golden Biotechnology Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Green Cross Cell Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Green Cross Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by H3 Biomedicine Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by HanAll Biopharma Co Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Horizon Pharma Plc, H1 2017

Hepatocellular Carcinoma – Pipeline by Humorigin Biotechnology Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Immatics Biotechnologies GmbH, H1 2017

Hepatocellular Carcinoma – Pipeline by Immune Therapeutics Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Immunicum AB, H1 2017

Hepatocellular Carcinoma – Pipeline by Immunitor Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Immunomedics Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Immunovative Therapies Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by In-Cell-Art SAS, H1 2017

Hepatocellular Carcinoma – Pipeline by Incyte Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Inspyr Therapeutics Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by InteRNA Technologies BV, H1 2017

Hepatocellular Carcinoma – Pipeline by Jenrin Discovery Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Johnson & Johnson, H1 2017

Hepatocellular Carcinoma – Pipeline by KAHR medical Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Karcinolys SAS, H1 2017

Hepatocellular Carcinoma – Pipeline by Kite Pharma Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Komipharm International Co Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Kowa Company Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Les Laboratoires Servier SAS, H1 2017

Hepatocellular Carcinoma – Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Lixte Biotechnology Holdings Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by MaxCyte Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by MedImmune LLC, H1 2017

Hepatocellular Carcinoma – Pipeline by Medivir AB, H1 2017

Hepatocellular Carcinoma – Pipeline by Merck & Co Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Merck KGaA, H1 2017

Hepatocellular Carcinoma – Pipeline by Merrimack Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Midatech Pharma Plc, H1 2017

Hepatocellular Carcinoma – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Mina Therapeutics Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by MTG Biotherapeutics Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by MultiCell Technologies Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by NeuroVive Pharmaceutical AB, H1 2017

Hepatocellular Carcinoma – Pipeline by NormOxys Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Novartis AG, H1 2017

Hepatocellular Carcinoma – Pipeline by NovaTarg Therapeutics Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Nymox Pharmaceutical Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Omeros Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Oncolys BioPharma Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by OncoMed Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by OncoTherapy Science Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Oneness Biotech Co Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Onxeo SA, H1 2017

Hepatocellular Carcinoma – Pipeline by Otsuka Holdings Co Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Panacea Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by PepVax Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Peregrine Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Pfizer Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Pharma Mar SA, H1 2017

Hepatocellular Carcinoma – Pipeline by PharmAbcine Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by PharmaEssentia Corp, H1 2017

Hepatocellular Carcinoma – Pipeline by Provecs Medical GmbH, H1 2017

Hepatocellular Carcinoma – Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Q BioMed Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by RedHill Biopharma Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Regulus Therapeutics Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Saronic Biotechnology Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Shenogen Pharma Group Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Sillajen Biotherapeutics, H1 2017

Hepatocellular Carcinoma – Pipeline by Simcere Pharmaceutical Group, H1 2017

Hepatocellular Carcinoma – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Taiwan Liposome Company Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by TC BioPharm Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by tella Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Tessa Therapeutics Pte Ltd, H1 2017

Hepatocellular Carcinoma – Pipeline by Therapure Biopharma Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Theravectys SA, H1 2017

Hepatocellular Carcinoma – Pipeline by Threshold Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Tiziana Life Sciences Plc, H1 2017

Hepatocellular Carcinoma – Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Tumorend LLC, H1 2017

Hepatocellular Carcinoma – Pipeline by UbiVac LLC, H1 2017

Hepatocellular Carcinoma – Pipeline by VasGene Therapeutics Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Vaxon Biotech, H1 2017

Hepatocellular Carcinoma – Pipeline by Vect-Horus SAS, H1 2017

Hepatocellular Carcinoma – Pipeline by Verlyx Pharma Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by VG Life Sciences Inc, H1 2017

Hepatocellular Carcinoma – Pipeline by Vicus Therapeutics LLC, H1 2017

Hepatocellular Carcinoma – Pipeline by Yooyoung Pharm Co Ltd, H1 2017

Hepatocellular Carcinoma – Dormant Projects, H1 2017

Hepatocellular Carcinoma – Dormant Projects, H1 2017 (Contd..1), H1 2017

Hepatocellular Carcinoma – Dormant Projects, H1 2017 (Contd..2), H1 2017

Hepatocellular Carcinoma – Dormant Projects, H1 2017 (Contd..3), H1 2017

Hepatocellular Carcinoma – Dormant Projects, H1 2017 (Contd..4), H1 2017

Hepatocellular Carcinoma – Dormant Projects, H1 2017 (Contd..5), H1 2017

Hepatocellular Carcinoma – Dormant Projects, H1 2017 (Contd..6), H1 2017

Hepatocellular Carcinoma – Discontinued Products, H1 2017

Hepatocellular Carcinoma – Discontinued Products, H1 2017 (Contd..1), H1 2017

Hepatocellular Carcinoma – Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

List of Figures

Number of Products under Development for Hepatocellular Carcinoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports